John Conyers: “This committee has marked up legislation that would unfortunately implement President Trump's vision for mass…”

In closing, I note that a broad coalition of public interest organizations, including Public Citizen, Americans for Financial Reform, the National Urban League, among others, strongly oppose H.R. 732. They warn: ``This measure would…

We should of course remain vigilant about pay-for-delay schemes, whereby branded drug manufacturers pay generic manufacturers to delay the entry of a version of branded drugs as the patent on the branded drug expires.

I am a cosponsor of her legislation with great pride.

Yes, they tell me there is a chance it could very well be struck down. But we will go ahead and run that risk.